Moss, 27 February 2018
Gentian Diagnostics AS announces its results for the 4th quarter and 2017 preliminary annual results. The highlights include:
- 11% growth in sales revenue compared to 4Q16, 14 % y/y despite loss of our largest distributor
- Increase in sales of fCAL turbo continues
- Favorable development for Cystatin C in China
Please find the report enclosed.
The report will also be made available on www.gentian.com.
For further information, please contact:
Bård Sundrehagen CEO, Gentian Diagnostics
E-mail: bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117
Njaal Kind CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
MeldingsID: 445248
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL